Niki BioSolutions, Inc. (NIKI)

NASDAQ: NIKI · USD

$1.87

-0.05 (-2.6%)· Recorded snapshot

Market cap	5.5M
Net income (ttm)	-2.2M
EPS (ttm)	-$2.86
Shares out	2.9M
Volume	5,063
Beta	-1.00

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -2.2M
EPS (ttm): -$2.86
Market cap: 5.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ホールド

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-17.1

P25 -113.8P50 -46.5P75 -0.9

ROIC-10.7

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All NIKI indicators

Market & fundamental data

Available fields

163

Groups with data

Currency

USD

Showing 163 of 163 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001734005
Company name	Niki BioSolutions, Inc.
Country	United States
Country code	US
CUSIP number	653942102
Earnings date	2026-11-10
Earnings time	bmo
Employees	1
Employees change	0
Employees growth	0%
Enterprise value	$7.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-07-21
Fiscal year end	December
Founded	2010
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US6539421023
Last refreshed	2026-10-28
Last stock split date	2023-01-23
Last stock split type	Reverse
Market cap	$5.5M
Market cap category	Nano-Cap
Next earnings date	2026-11-10
Options	No
Price	$1.87
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	NIKI
U.S. state	New Jersey
Website	https://www.aptorumgroup.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-152.9%
FCF / EV yield	-35.18%
FCF yield	-45.62%
P/B ratio	0.07x
Price / tangible book value	0.26x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.2M
ROA	-10.04%
ROA (5Y)	-26.56%
ROCE	-22.41%
ROE	-17.05%
ROE (5Y)	-53.44%
ROIC	-10.68%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-2.8M
EPS	$-2.86
FCF per share	$-0.88
Financing cash flow	$1.7M
Free cash flow	$-2.6M
Investing cash flow	$-65,000
Net cash flow	$-922,723
Net income	$-2.2M
Operating income	$-2.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$26.75
Debt / equity	0.28
Interest coverage	-26.71
Long-term assets	$15.1M
Long-term liabilities	$189,000
Net cash (debt)	$-1.7M
Net cash / market cap	-29.68%
Net debt / equity	0.13
Piotroski F-Score	0
Shareholders' equity	$12.4M
Tangible book value	$21.8M
Tangible book value per share	$26.75
Total assets	$17.1M
Total cash	$1.8M
Total debt	$3.5M
Total liabilities	$4.7M
WACC	0.16%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$2M
Current liabilities	$4.5M
Current ratio	0.45
Net working capital	$-801,089
Quick ratio	0.41
Working capital	$-2.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-23.85%
Dividend yield	0%
Shareholder yield	-23.85%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$3.40
1D price change	-2.6%
1M price change	-60.71%
1M total return	-60.71%
1W price change	-6.5%
1W total return	-6.5%
1Y price change	23.84%
1Y return CAGR	23.86%
1Y total return	23.84%
20-day SMA	$2.98
200-day SMA	$2.77
3M price change	-77.76%
3M total return	-77.76%
3Y price change	4.47%
3Y return CAGR	1.47%
3Y total return	4.47%
50-day SMA	$4.88
50-day SMA vs 200-day SMA	50over200
52-week high	$12.24
52-week high date	2026-07-20
52-week low	$0.60
52-week low date	2026-07-17
5Y price change	-92.64%
5Y return CAGR	-40.66%
5Y total return	-92.64%
6M price change	108.82%
6M total return	108.82%
All-time high	$332.80
All-time high date	2019-06-04
All-time low	$0.46
All-time low date	2024-11-18
Average true range (ATR)	$0.38
Average volume	14.8K
Beta (1Y)	-5.64
Beta (2Y)	-0.46
Beta (5Y)	-1
Change from 52-week high	-84.72%
Change from 52-week low	211.67%
Change from all-time high	-99.44%
Change from all-time low	306.52%
Change from open	-3.61%
Day's gap	1.04%
Dollar volume	$9,468
High price	$1.96
Low price	$1.86
Monthly RSI	45.73
Open price	$1.94
Position in 52-week range	13.59%
Premarket change	0.52%
Premarket close	$1.92
Premarket price	$1.93
Premarket volume	806
Previous close	$1.92
Price vs 150-day SMA	-44.98%
Price vs 20-day SMA	-37.23%
Price vs 200-day SMA	-32.47%
Price vs 50-day SMA	-61.67%
Relative volume	0.34
RSI	21.95
Sharpe ratio	0.83
Sharpe ratio (3Y)	0.72
Sharpe ratio (5Y)	0.51
Sortino ratio	14.07
Sortino ratio (3Y)	6.54
Sortino ratio (5Y)	3.87
Volume	5.1K
Weekly RSI	39.12
YTD price change	76.42%
YTD total return	76.42%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Shares change (QoQ)	0%
Shares change (YoY)	23.85%
Shares held by insiders	57.33%
Shares outstanding	2.9M
Short % of shares	0.5%
Short ratio	0.1 days

Deeper analysis on NIKI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NIKI report

Is a complete NIKI research report available?

No complete published report is available for Niki BioSolutions, Inc. (NIKI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Niki BioSolutions, Inc. (NIKI)

Price

Financial snapshot

Fair-value bridge

Latest news · NIKI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NIKI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NIKI

Frequently asked questions